The contributions to allorecognition of polymorphic amino acids in the HLA-DR7 beta 1 chain were analyzed by using mutant DR7 beta 1 chains with single amino acid substitutions at position 4, 11, 13, 25, 30, 37, 57, 60, 67, 70, 71, 74, or 78. Transfectants expressing mutant DR7 molecules were used as stimulators for six DR7-alloreactive T cell clones. The majority of the substitutions had profound effects on the ability of the DR7 molecule to stimulate one or more T cell clones. Nine of the 13 substitutions completely abrogated recognition by at least one clone. The finding that each of the substitutions in the beta-strands in the floor of the peptide binding groove affected T cell allorecognition supports the model of allorecognition in which the complex of a self-peptide bound to a class II molecule is recognized by the TCR. Interestingly, the substitution at position 4, which is predicted to be located outside the peptide binding groove, decreased the ability of the DR7 molecule to stimulate some clones. Each of the DR7-alloreactive T cell clones had a unique reactivity pattern in response to the different mutant molecules, indicating that the TCR of each clone recognized the DR7 molecule differently. Surprisingly, many of the mutant DR7 molecules induced proliferation by one or more clones that was greater than 125% of the proliferation induced by the wild-type DR7 molecule. These data indicate that multiple polymorphic residues, predicted in the class II model to be located in both the beta-strands and alpha-helix of the DR7 beta 1 chain, contribute to allorecognition of the DR7 molecule.

Download full-text PDF

Source

Publication Analysis

Top Keywords

dr7 molecule
20
beta chain
12
mutant dr7
12
cell clones
12
dr7
9
hla-dr7 beta
8
cell allorecognition
8
dr7 beta
8
dr7 molecules
8
dr7-alloreactive cell
8

Similar Publications

Article Synopsis
  • - Rhupus is a rare syndrome that combines symptoms of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), characterized by specific autoantibodies and erosive polyarthritis.
  • - This study analyzed the HLA-DR genetic profiles of 9 patients diagnosed with rhupus, finding that it commonly occurs in women with early RA symptoms and noteworthy serological markers like ANA, RF, and anti-CCP.
  • - Results indicated a higher prevalence of certain HLA-DR types (HLA-DR1 and DR9) in rhupus patients compared to those with RA or SLE, suggesting potential for early identification of rhupus before an overlap diagnosis is made. *
View Article and Find Full Text PDF

A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2.

Virus Res

January 2023

Department of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu, China 210009. Electronic address:

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection remains in a global pandemic, and no eradicative therapy is currently available. Host T cells have been shown to play a crucial role in the antiviral immune protection and pathology in Coronavirus disease 2019 (COVID-19) patients; thus, identifying sufficient T-cell epitopes from the SARS-CoV-2 proteome can contribute greatly to the development of T-cell epitope vaccines and the precise evaluation of host SARS-CoV-2-specific cellular immunity. This review presents a comprehensive map of T-cell epitopes functionally validated from SARS-CoV-2 antigens, the human leukocyte antigen (HLA) supertypes to present these epitopes, and the strategies to screen and identify T-cell epitopes.

View Article and Find Full Text PDF

Human Complement C4B Allotypes and Deficiencies in Selected Cases With Autoimmune Diseases.

Front Immunol

December 2021

Center for Microbial Pathogenesis, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, United States.

Human complement C4 is one of the most diverse but heritable effectors for humoral immunity. To help understand the roles of C4 in the defense and pathogenesis of autoimmune and inflammatory diseases, we determined the bases of polymorphisms including the frequent genetic deficiency of C4A and/or C4B isotypes. We demonstrated the diversities of C4A and C4B proteins and their gene copy number variations (CNVs) in healthy subjects and patients with autoimmune disease, such as type 1 diabetes, systemic lupus erythematosus (SLE) and encephalitis.

View Article and Find Full Text PDF

Clinical Outcome of Kidney Transplant Patients on the Allograft Function, Loss, Effects of HLA-DQB1-DSA, and Graft Survival.

Transplant Proc

September 2021

IMUNOLAB-Laboratory of Histocompatibility, Belo Horizonte, Minas Gerais, Brazil; Institute of Education and Research of the Hospital Santa Casa, Belo Horizonte, Minas Gerais, Brazil. Electronic address:

Introduction: Matching for HLA-DQB1 molecules and anti-DQ donor-specific antibodies (DSAs) has been less studied to allocate transplants from deceased donors in developed countries. The aim of this study was to evaluate the clinical outcome of 519 kidney transplant recipients on the allograft function, loss, and survival and with emphasis on effects of HLA-DQB1-DSA at minimum of 10 years' follow-up.

Methods: Five hundred nineteen kidney transplant patients were allocated into 3 groups (G) by immunologic profiles, namely, G1 (SPI-SAB HLA-DQ negative [DQ]), G2 (SPI-SAB HLA-DQ positive DSA negative [DQ/DSA]), and G3 (SPI-SAB HLA-DQ DSA positive [DQ DSA]), and the outcomes were reported until 10 years after transplantation.

View Article and Find Full Text PDF

Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients.

Cancer Immunol Immunother

October 2019

Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Inserm UMRS 1138, "Cancer, Immune Control and Escape" Laboratory, Centre de Recherche des Cordeliers, Paris, France.

Article Synopsis
  • Preclinical and clinical studies indicate that cancer treatment with antitumor antibodies generates a specific immune response, particularly involving CD4 T cells.
  • This research identifies 21 T cell epitopes derived from the human CD20 protein, which are restricted by various HLA types and can stimulate T cell activity in both healthy individuals and lymphoma patients.
  • These identified CD20-derived peptides have potential as therapeutic agents to enhance or track T cell responses in patients receiving anti-CD20 treatments like rituximab.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!